PARIS and CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO — NASDAQ: NBTX – the ”Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”), one…Read More
NANOBIOTIX Announces License Agreement for Worldwide Codevelopment and Commercialization of Potential FirstInClass Radioenhancer NBTXR3
